Tenaya Therapeutics Announces Progress In Gene Therapies TN-201 And TN-401 For Cardiomyopathies; Dosing Started In Cohort 2 Of MyPEAK-1 Phase 1b/2 Trial; Cohort 1 Data Expected H1 2025; Initial Data From RIDGE-1 Trial Of TN-401 Expected In H2 2025
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $6 to $19
Tenaya Therapeutics Is Maintained at Buy by Chardan Capital
Tenaya Therapeutics Analyst Ratings
Cautious Optimism for Tenaya Therapeutics' TN-201: Early Phase Study Shows Promising Efficacy and Safety
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
